Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05204303
Other study ID # FGC-22-001
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 1, 2022
Est. completion date July 2023

Study information

Verified date August 2022
Source The Functional Gut Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Comparing the fluorescence signatures from mouthwash samples of patients with laryngopharyngeal reflux (LPR) and healthy volunteers.


Description:

The investigators aim to test if the biosensing platform Pandra, developed by Rosa Biotech, may be suitable to distinguish patients with LPR symptoms, both with and without objective evidence of gastroesophageal reflux disease (GORD), vs healthy volunteers due to their expected inflammation and cell changes in the laryngo-pharyngeal region. The investigators intend to analyse 20 samples of mouthwash solutions from each of the following groups: A. Patients with symptoms of LPR and objective evidence of GORD B. Patients with symptoms of LPR and no objective evidence of GORD C. Healthy volunteer group


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date July 2023
Est. primary completion date June 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Healthy Volunteers Inclusion Criteria: - Participant is Aged 18 or above - Participant has capacity to understand written English - Participant is not on regular prescription medicines - Participant has an RSI score of 0 - Participant has a body mass index (BMI) of 18.5 - 34.9 kg/m2 (bounds included) Exclusion Criteria: - Participant has experienced any symptoms of LPR or GORD symptoms in the past year - Participant has taken any medication for GORD/LPR in the past year (e.g. proton pump inhibitors, h2 antagonists, over the counter antacids) - Participant has active oral disease - Participant has a significant medical diagnosis Patients with symptoms of LPR Inclusion Criteria: - Participant is Aged 18 or above - Participant has capacity to understand written English - Participant has an RSI score of >13 - Participant has a body mass index (BMI) of 18.5 - 34.9 kg/m2 (bounds included - Participant has been referred for 24hr ambulatory pH-impedance monitoring Exclusion Criteria: - Participant has active oral disease - Participant has other ongoing health problems that could account for their LPR symptoms. - Participant has NOT undergone nasoendoscopy within last 6 months OR does not have one scheduled within next 6 weeks - Previous antireflux surgery (e.g. fundoplication or magnetic sphincter augmentation) - Previous bariatric surgery (e.g. gastric bypass or sleeve gastrectomy)

Study Design


Intervention

Diagnostic Test:
24-hour pH-impedance monitoring
Ambulatory transnasal reflux device to detect reflux events in the oeosphagus and pharynx.
Other:
Symptom questionnaires
Reflux Symptom Index (RSI) Gastroesophageal Reflux Disease Questionnaire (GERDQ) Short-form Esophageal Hypervigilance and Anxiety Scale (SF-EHAS)
ROME IV Diagnostic Questionnaire
A symptom-based questionnaire used to diagnose disorders of gut-brain interaction (DGBI)

Locations

Country Name City State
United Kingdom The Functional Gut Clinic Manchester Greater Manchester

Sponsors (2)

Lead Sponsor Collaborator
The Functional Gut Clinic Rosa Biotech

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the detection strength of differences in fingerprints between the three participant groups. 10-months
Secondary Determine the differences in fingerprints between samples within one group to assess background noise. 10-months
Secondary Determine the feasibility of mouthwash on Pandra platform. 10-months
See also
  Status Clinical Trial Phase
Recruiting NCT06025773 - A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121 Phase 1
Recruiting NCT06280664 - Efficacy Of Hiatal Closure For GERD
Recruiting NCT05359965 - Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF N/A
Completed NCT04202692 - Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment N/A
Active, not recruiting NCT03646045 - Transpyloric Feeding for Prevention of Micro-aspiration
Completed NCT04268719 - Near Focus NBI-Driven Artificial Intelligence for the Diagnosis of Gastro-Oesophageal Reflux Disease
Active, not recruiting NCT04614974 - Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia Phase 1/Phase 2
Terminated NCT05579444 - Systems Biology of Gastrointestinal and Related Diseases
Recruiting NCT03868267 - Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting
Terminated NCT04028466 - Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features Phase 4
Active, not recruiting NCT05371717 - Domiciliary Management of Dental Erosion in Patients With GERD With Biomimetic Hydroxyapatite N/A
Recruiting NCT05066594 - Observational Registry of Transoral Incisionless Fundoplication (TIF) for Gastroesophageal Reflux Disease (GERD)
Completed NCT03476265 - Lower Esophageal Sphincter (LES) Stimulation in Patients With Ineffective Esophageal Motility N/A
Completed NCT03143608 - GERD Treatment With Transoral Incisionless Fundoplication (TIF) Following Hiatal Hernia Surgery N/A
Completed NCT04436159 - Partial Versus Total Fundoplication in the Surgical Repair of Para-esophageal Hernia. N/A
Completed NCT03258528 - Effect of Right Lateral Position on Ventilated Preterm Neonates N/A
Active, not recruiting NCT04500288 - The Effect of Positional Therapy on Symptoms of Gastroesophageal Reflux Disease: A Prospective Pilot Study N/A
Completed NCT04262648 - Randomized Placebo-controlled Study of L. Reuteri NCIMB 30351 in GI Functional Disorders and Food Allergy in Newborns N/A
Recruiting NCT04846010 - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 Phase 1/Phase 2
Active, not recruiting NCT03835663 - The Bacterial Composition of the Stomach in Reflux Disease